Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB | P24530 | 19/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | TSPO | P30536 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632084 | 0.94 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380477 | 0.92 | EDNRA (0.84) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380766 | 0.91 | EDNRB (0.84) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380471 | 0.91 | EDNRA (0.83) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9891391 | 0.88 | EDNRB (0.79) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380475 | 0.88 | EDNRA (0.79) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL999054 | 0.87 | EDNRB (0.77) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.86 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380500 | 0.86 | EDNRA (0.76) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380501 | 0.85 | EDNRA (0.75) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2190837-B1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-06-07 | — | — | US | disclosed |
| WO-2009024906-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142716-A1 | 4-PYRIMIDINESULFAMIDE DERIVATIVE | EDNRB, EDNRA, TBXA2R | EDNRA 2/4885EDNRB 1/4885SLC6A2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.